Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 968 across all filing types
Latest filing 2024-10-24 Environmental & Social …
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
ArcticZymes Highlights Industry-Leading Success at ESGCT 2024
Environmental & Social Information Classification · 99% confidence The document is an announcement from ArcticZymes Technologies ASA detailing their participation and the scientific breakthroughs presented by their partners (ACIB and Oxford Biomedica) at the ESGCT 2024 conference. The content focuses on scientific achievements, enzyme performance comparisons (M-SAN HQ vs. Benzonase), and quotes from the CEO regarding industry interest. This type of material, which highlights scientific progress and industry engagement rather than formal financial results (10-K, ER, IR) or governance changes (MANG, DEF 14A), fits best under the general category of Investor Relations or specific scientific/industry updates. Since there is no specific category for 'Scientific Conference Update' or 'Industry News,' and the content is promotional/informational aimed at investors and the scientific community, it aligns most closely with general Investor Relations material. However, given the strong focus on ESGCT and scientific validation, it is not a standard Earnings Release (ER) or Interim Report (IR). It is not a formal regulatory filing like a 10-K or a proxy statement. It is an announcement about industry activity. Given the options, 'Regulatory Filings' (RNS) is the broadest fallback, but 'Investor Presentation' (IP) often covers strategic updates, though this is an announcement *about* presentations. Since the document is an announcement highlighting scientific validation and industry presence, and it is relatively short (4198 chars), it could potentially be an RPA if it were announcing the *release* of a formal report. Since it is reporting on an *event* and scientific findings, and it is not a formal financial report, it is best classified as a general informational release. Given the options, and recognizing it is not a formal financial filing, 'Regulatory Filings' (RNS) serves as the most appropriate catch-all for non-standard, non-financial, non-governance announcements, or potentially 'Investor Presentation' (IP) if interpreted as a summary of investor-facing material. Given the context of reporting on conference highlights, RNS is the safest general classification for non-standard corporate news.
2024-10-24 English
ArcticZymes Highlights Industry-Leading Success at ESGCT 2024
Environmental & Social Information Classification · 99% confidence The document is a press release from ArcticZymes Technologies ASA highlighting their enzyme innovations presented at the European Society of Gene and Cell Therapy (ESGCT) 2024 conference. It details scientific achievements, collaborations (with acib and Oxford Biomedica), and quotes from the CEO. This content is promotional and informational, focusing on scientific progress and market relevance, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). It is best classified as a general corporate announcement or news release. Since there is no specific category for 'Press Release' or 'Scientific Update', and it is not a formal regulatory filing, the most appropriate fallback category is 'Regulatory Filings' (RNS), which often serves as a catch-all for significant, non-standard corporate announcements released to the market, or potentially 'Investor Presentation' (IP) if it were structured as a presentation deck, but given the format, RNS is safer as a general announcement.
2024-10-24 English
ArcticZymes Technologies to present at the Pareto Securities 15th Healthcare Conference
Investor Presentation Classification · 98% confidence The document text consists of slides from a presentation titled 'A Norwegian biotech growth ambitions' presented at the 'Pareto Healthcare Conference' on September 19, 2024. It covers company overview, organization, financials, product details, and strategic priorities. This format and content strongly indicate an Investor Presentation (IP), which is designed to communicate strategy and performance to investors, distinct from a formal regulatory filing like a 10-K or an Earnings Release (ER) which focuses purely on period results.
2024-09-19 English
ArcticZymes Technologies to present at the Pareto Securities 15th Healthcare Conference
Report Publication Announcement Classification · 98% confidence The document is very short (614 characters) and announces that ArcticZymes Technologies will present at the Pareto Securities 15th Healthcare Conference today, September 19, 2024. It explicitly states, 'Please find the presentation enclosed'. This structure—a brief announcement stating that presentation materials are attached or enclosed—fits the definition of a Report Publication Announcement (RPA), as it is announcing the availability of presentation materials rather than being the presentation itself or a major regulatory filing like a 10-K or IR. It is not a standard regulatory filing (RNS) because it specifically relates to an investor event presentation.
2024-09-19 English
ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper published in Select Science on Advancing Viral Vector Manufacturing
Report Publication Announcement Classification · 98% confidence The document is a press release dated September 17th, 2024, announcing that ArcticZymes Technologies has released a new whitepaper in Select Science regarding viral vector manufacturing. The text explicitly states that the whitepaper has been 'released' and provides a link to view the full paper. Since the document itself is an announcement about the publication of external material (a whitepaper) rather than the whitepaper or a formal regulatory filing (like 10-K, ER, or IR), it fits the definition of a Report Publication Announcement (RPA). The document length (3528 chars) is short, supporting the 'announcement' classification over the full report classification.
2024-09-17 English
ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper published in Select Science on Advancing Viral Vector Manufacturing
Regulatory Filings Classification · 90% confidence The document is a press release dated September 17th, 2024, announcing that ArcticZymes Technologies has released a 'timely whitepaper' in Select Science regarding their salt-active nucleases for viral vector manufacturing. The text focuses on promoting this new publication and the company's leadership in the field, rather than being the whitepaper itself or a formal regulatory filing like a 10-K or ER. Since it is an announcement about the publication of external informational material (a whitepaper), and it does not fit into the specific categories like Earnings Release (ER), Interim Report (IR), or a formal regulatory filing, it falls best under the general category for miscellaneous announcements or regulatory filings that don't fit elsewhere, which is RNS (Regulatory Filings). However, given the content is purely promotional/informational about a published paper, and not a mandatory regulatory disclosure, it is closest to a general announcement. If 'RPA' (Report Publication Announcement) were strictly for company-issued reports, RNS is the best fit for this type of external publication announcement that doesn't match other specific types.
2024-09-17 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.